Biochem/physiol Actions
Imidazoline agonist; more potent than efaroxan in inducing insulin release from β cells; H1 histamine receptor antagonist.
Features and Benefits
This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Packaging
25 g in poly bottle
This product has met the following criteria to qualify for the following awards: